Skip to main content

Keep An Eye On Regeneron

Ophthotech ’s ( OPHT ) loss is a big gain for Regeneron ( REGN ). The drug maker’s stock spiked 5% to $391.27 today after a rival’s experimental treatment for age-related macular degeneration, an eye disease that causes blindness in the elder, failed in late-stage clinical trials.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.